Kronos Bio Valuation
| KRONDelisted Stock | USD 0.88 0.00 0.00% |
Today, the firm appears to be overvalued. Kronos Bio secures a last-minute Real Value of $0.71 per share. The latest price of the firm is $0.88. Our model forecasts the value of Kronos Bio from analyzing the firm fundamentals such as Shares Outstanding of 60.97 M, operating margin of (3.42) %, and Return On Equity of -0.59 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kronos Bio's price fluctuation is abnormally volatile at this time. Calculation of the real value of Kronos Bio is based on 3 months time horizon. Increasing Kronos Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kronos Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kronos Stock. However, Kronos Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.88 | Real 0.71 | Hype 0.88 | Naive 0.82 |
The intrinsic value of Kronos Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kronos Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kronos Bio helps investors to forecast how Kronos stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kronos Bio more accurately as focusing exclusively on Kronos Bio's fundamentals will not take into account other important factors: Kronos Bio Total Value Analysis
Kronos Bio is now estimated to have valuation of (21.99 M) with market capitalization of 53.65 M, debt of 24.9 M, and cash on hands of 267.89 M. The negative valuation of Kronos Bio may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kronos Bio fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(21.99 M) | 53.65 M | 24.9 M | 267.89 M |
Kronos Bio Investor Information
About 24.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kronos Bio recorded a loss per share of 1.07. The entity had not issued any dividends in recent years. The firm had 3:2 split on the 3rd of November 2003. Based on the analysis of Kronos Bio's profitability, liquidity, and operating efficiency, Kronos Bio is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Kronos Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kronos Bio has an asset utilization ratio of 7.92 percent. This suggests that the Company is making $0.0792 for each dollar of assets. An increasing asset utilization means that Kronos Bio is more efficient with each dollar of assets it utilizes for everyday operations.Kronos Bio Ownership Allocation
Kronos Bio maintains a total of 60.97 Million outstanding shares. Kronos Bio holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kronos Bio Profitability Analysis
The company reported the previous year's revenue of 9.85 M. Net Loss for the year was (86.08 M) with profit before overhead, payroll, taxes, and interest of 9.19 M.About Kronos Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Kronos Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Kronos Bio based exclusively on its fundamental and basic technical indicators. By analyzing Kronos Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Kronos Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kronos Bio. We calculate exposure to Kronos Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kronos Bio's related companies.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company was incorporated in 2017 and is headquartered in San Mateo, California. Kronos Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.
Kronos Bio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 60.1 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Kronos Stock
If you are still planning to invest in Kronos Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kronos Bio's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |